AGM presentation:
Kidney survival study (2020)2:“reductions ~10% in proteinuria translated to clinically meaningfuldifferences in eGFR slope 0.5 - 1 mL/min/ 1.73 m2 per year”
Dimerix Phase 2 study observed a 17% reduction in proteinuria versus placebo
Placebo which is the gold standard achieved ~17% so double the reduction with DMX-200. ADVANCE done their DD and paid $10m upfront imho adds weight DMX-200 does have merits.
Dimerix (ASX: DXB) Discussion Thread, page-152
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.015(4.62%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 35.0¢ | 32.5¢ | $1.004M | 2.972M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 709817 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 176092 | 1 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.5¢ |
Change
0.015 ( 6.12 %) |
||||
| Open | High | Low | Volume | ||
| 32.5¢ | 35.0¢ | 32.5¢ | 2371193 | ||
| Last updated 15.55pm 14/05/2024 ? | |||||
| DXB (ASX) Chart |